Candell Therapeutics Publicizes Late-Breaking Oral Presentation at SITC Annual Assembly with Information on CAN-2409 in Mixture with Nivolumab in a Part 1 Mechanistic Scientific Trial in Sufferers with Excessive-Grade Glioma

Candle Therapeutics The mix of nivolumab and CAN-2409 given throughout neurosurgery was usually effectively tolerated with no vital further toxicities in comparison with normal of care Systemic immune activation noticed in peripheral blood after administration of CAN-2409/valacyclovir earlier than nivolumab remedy Median total survival (mOS) for sufferers with a methylated MGMT promoter was 30.6 months … Read more